featured
Safety of JAK Inhibitors for Short-term Treatment of Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety of Janus Kinase (JAK) Inhibitors in the Short-term Treatment of Atopic Dermatitis
Int. J. Dermatol 2021 Aug 22;[EPub Ahead of Print], H Wood, A Chandler, N Nezamololama, K Papp, MJ GooderhamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.